Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

Summary

-Evaluate the efficacy and safety of Shenyankangfu Tablets to control the proteinuria of patients with primary glomerulonephritis compare with Losartan potassium.

Timeline

Start

2014-02

Primary completion

2015-07

Completion

—

Outcome

Mixed primary results

paper SYKFT group after 48 weeks was 8.78% ± 2.56% (P = 0.006) more than that in the losartan 50 mg group PMID 33589406 ↗

paper which was 0.51% ± 2.54% (P = 1.000) less than that in the losartan 100 mg group. PMID 33589406 ↗

paper With a superiority threshold of 15%, neither was statistically significant. PMID 33589406 ↗

Publications

• Wu J, Duan SW, Yang HT, Deng YY, Li W, He YN, Ni ZH, Zhan YL, Lin S, Guo ZY, Zhu J, Fang JA, Liu XS, Wang LH, Wang R, Wang NS, Cheng XH, He LQ, Luo P, Sun SR, Sun JF, Yin AP, Jiang GR, Chen HY, Liu WH, Lin HL, Liang M, Ma L, Chen M, Song LQ, Chen J, Zhu Q, Xing CY, Li Y, Gao JN, Li RS, Li Y, Zhang H, Lu Y, Zhou QL, Fu JZ, He Q, Cai GY, Chen XM. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial. J Integr Med. 2021 Mar;19(2):111-119. doi: 10.1016/j.joim.2021.01.009. Epub 2021 Jan 30.
• Kou J, Wu J, Yang HT, He YN, Fang JA, Deng YY, Xie YS, Nie LF, Lin HL, Cai GY, Chen XM. Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial. Trials. 2014 Dec 5;15:479. doi: 10.1186/1745-6215-15-479.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Losartan	Other / unclassified	50 mg	Oral
Subject	Losartan	Other / unclassified	100 mg	Oral
Subject	Shenyankangfu tablets	Traditional medicine (herbal / TCM)	2.4 g	Oral

Indications